ArticleOpen life sciences2026
High-dose SFRP2 attenuates fibrosis and promotes angiogenesis via Wnt signaling modulation in diabetic erectile dysfunction.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated whether high-dose secreted frizzled-related protein 2 (SFRP2) attenuates fibrosis and improves endothelial function under diabetic-like conditions. Diabetic erectile dysfunction (ED) is marked by progressive corpus cavernosum fibrosis and endothelial dysfunction, driven partly by dysregulated Wnt signaling. Primary human corpus cavernosum fibroblasts were stimulated with bone morphogenetic protein 1 (BMP1, 50 ng/mL) or high glucose (HG, 30 mM), with or without SFRP2, and fibrotic responses were assessed by Western blot for collagen I/IV and Wnt markers. Endothelial dysfunction was modeled in human umbilical vein endothelial cells (HUVECs) using tube formation, proliferation, and apoptosis assays. BMP1 and HG increased SFRP2 expression and collagen accumulation, mimicking low-dose SFRP2 effects. In contrast, high-dose SFRP2 (20 µM) suppressed fibrosis, reducing collagen I/IV expression by 40-62 % and downregulating Wnt3a and Wnt5a/b by 40-66 %. High-dose SFRP2 also enhanced angiogenesis and reduced apoptosis by ∼50 % under HG stress. These findings suggest that high-dose SFRP2 mitigates fibrosis and promotes angiogenesis, likely through inhibition of canonical Wnt signaling. As all results were obtained from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.